The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...

Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...

Cathie Wood is one of the country's best known growth investors, but sometimes, she acts like an umbrella-toting value ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue ...

Exact Sciences is laying off 4% of its overall workforce, including 80 positions at the headquarters in Madison.

NasdaqCM:EXAS 1 Year Share Price vs Fair Value Explore Exact Sciences's Fair Values from the Community and select ...

Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s ...

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences (EXAS -2.68%), the maker of the noninvasive colon cancer diagnostic Cologuard, posted better-than-expected financial results for the second quarter of 2023 after the closing bell ...

Last year, Exact Sciences burned through $223.6 million in cash just from its day-to-day operations. And that was a significant increase from the $102.2 million it used up in the previous year.